Oncologists in a Survey Detail Managed Care's 'Hassle Factor'

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

BETHESDA, Md--Managed care, more than other types of medical coverage, imposes a "hassle factor" on oncologists and their patients, and restrains patients from participating in clinical trials, a survey by the Association of Community Cancer Centers (ACCC) has found.

BETHESDA, Md--Managed care, more than other types of medical coverage,imposes a "hassle factor" on oncologists and their patients,and restrains patients from participating in clinical trials, a surveyby the Association of Community Cancer Centers (ACCC) has found.

The ACCC sent four-page questionnaires to 2,000 randomly selected adultmedical oncologists and received 322 (16.1%) usable responses. The associationconducted the survey to measure the perceived impact of managed care onthe ability of oncologists to deliver care and to determine if paymentdenials affect their clinical judgment.

"We call this the 'hassle factor' survey," ACCC president-electJames L. Wade III, MD, said at the National Cancer Advisory Board (NCAB)meeting.

Among the survey findings:

Contract restrictions: Two thirds of coverage contracts imposeda gatekeeper; 29% of physicians reported that their patients regularlyhad to switch oncologists due to contract provisions; and 32% said thatpatients had to make prolonged journeys for services due to their contractrestrictions.

Clinical trials: More than one third of oncologists (37%) saidthat insurers had refused to allow patients to participate in a clinicaltrial; 77.3% of the oncologists hesitated to enroll managed care patientsin clinical trials because of previous denials, compared with 41.8% forMedicare patients, 33.9% for patients in capitated plans, and 32.2% forpatients with commercial insurance.

Transplants and chemotherapy: Most respondents (87.4%) said thatthey hesitated to prescribe a bone marrow transplant and 53.7% hesitatedto prescribe expensive chemotherapy for patients in managed care plans.

Increased paperwork: More than half of those surveyed (56%) reportedthat their practices had added staff because of increased paperwork; 55%reported difficulty reaching plans to clarify coverage; 43% of the oncologistssaid they personally handled managed care appeals. "There is realdifficulty in getting answers back from plans as to what is covered,"Dr. Wade said.

Difficulties among practices varied, in an inverted U-shaped curve.The quartile of practices with the least managed care patients had theleast problems. The top quartile had the second least problems, while thetwo middle quartiles reported "the most hassles," Dr. Wade said.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content